Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See more on REPL stock here.

WASHINGTON—The videos were splashed across cable news—and President Trump was paying attention. Working from the Oval Office as a winter storm barreled toward the nation’s capital, Trump watched as ...

In a report released on January 14, Evan Seigerman from BMO Capital reiterated a Hold rating on Replimune Group, with a price target of $11.00. The company’s shares closed yesterday at $7.71.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in The Trade Desk Inc (Symbol: TTD), where a total of 69,953 contracts have traded so far, ...

One of the best apps on the iPhone that isn't on Android or Windows is Apple Notes. When Apple locks you in its walled garden, Notes is the consolation prize that makes you forget that you're ...

Draper took to X, sharing his recent interview on the Founders Room Podcast, in which he talked about the increasing dominance of Bitcoin in the blockchain space. “I think there’s a gravitational pull ...

GameSpot may get a commission from retail offers. Early access for the Call of Duty: Black Ops 7 beta starts today, and Treyarch has released some new patch notes regarding changes and new additions ...

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Well before market open that morning, Anupam Rama from J.P. Morgan ...

Mr. Kramon is a former New York Times editor and a lecturer at the Stanford Business School. Your assignment today: Write a note of gratitude to someone to whom your thanks are overdue. It might be a ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...